Here are what the editors at HealthDay consider to be the most important developments in Diabetes & Endocrinology for September 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Increased Cardiovascular Risk for Diclofenac Initiators
FRIDAY, Sept. 28, 2018 (HealthDay News) — Diclofenac initiators have increased cardiovascular risk compared with non-initiators, according to a study published online Sept. 4 in The BMJ.
Physicians Often Don’t Address Their Burnout
FRIDAY, Sept. 28, 2018 (HealthDay News) — More than half of physicians experience burnout, and many do not seek treatment for burnout, according to a report published in the American Medical Association’s AMA Wire.
Business Degree Increasingly Useful for Doctors
THURSDAY, Sept. 27, 2018 (HealthDay News) — Having a Master of Business Administration degree (M.B.A.) can help doctors with important, practice-related decisions, according to a report published recently in Physician Practice.
Practices Should Set Rules for Staff Social Media Use
THURSDAY, Sept. 27, 2018 (HealthDay News) — Medical practices can take steps to avoid problems related to use of social media by staff members, according to an article published in Medical Economics.
Burnout, Career Choice Regret Prevalent in U.S. Residents
WEDNESDAY, Sept. 26, 2018 (HealthDay News) — Symptoms of burnout and career choice regret are prevalent among U.S. resident physicians, according to a study published in the Sept. 18 issue of the Journal of the American Medical Association.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Many Countries Failing on Non-Communicable Dz Death Targets
WEDNESDAY, Sept. 26, 2018 (HealthDay News) — Many countries are falling short on targets to reduce mortality from non-communicable diseases (NCDs), according to a study published in the Sept. 22 issue of The Lancet.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Lorcaserin Facilitates Weight Loss in Overweight, Obese
WEDNESDAY, Sept. 26, 2018 (HealthDay News) — Lorcaserin facilitates sustained weight loss without increasing the rate of major cardiovascular events among overweight or obese patients, according to a study published in the Sept. 20 issue of the New England Journal of Medicine.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Total Diabetes at 14 Percent in U.S. Adults for 2013-2016
Very Low-Carb Diet Shows Greater Cardiometabolic Benefits Than Other Diets .jpg)
Time-Restricted Eating May Help Patients With Type 1 Diabetes 
Vascular Burden in Midlife Linked to Increased Risk for Dementia, Death 
GLP-1 Receptor Agonists Tied to Increased Risk for Alopecia 
Food-Based Support Aids Type 2 Diabetes Outcomes 
Hypoglossal Nerve Stimulation May Offer Long-Term Cardiovascular Benefits in OSA 
Burden of Myocardial Dysfunction Elevated for Individuals With Psoriasis 
2017 to 2022 Saw More Than Doubling in Use of GLP-1 Receptor Agonists 
